About
Hyperspectral retinal camera + AI to assess cerebral amyloid status (Alzheimer's risk) from the eye. Analysis algorithm holds FDA Breakthrough Device designation.
HQ: Montreal, Canada
Funding
CA$24.8M Series A (2021); ~$33.4M total
—Company profile
awAIr — a cerebral-amyloid status test on a 510(k)-cleared hyperspectral retinal camera.
Hyperspectral retinal camera + AI to assess cerebral amyloid status (Alzheimer's risk) from the eye. Analysis algorithm holds FDA Breakthrough Device designation.
HQ: Montreal, Canada